



2018 NephroNet Nephrology Update

JULY 27 - 29, 2018 | FOUR SEASONS HOTEL | ATLANTA, GA

Advancing the Care of Chronic Kidney Disease Through Collaboration


Welcome Note from the President

On behalf of NephroNet and our Board Members, I am pleased to welcome all attendees to Atlanta and the first NephroNet Nephrology Update meeting.

Further, I want to thank you for your time and support of the NephroNet organization. It is because of the efforts of you and other nephrology advocates that NephroNet has been able to grow and impact the development of new therapies for patients with chronic kidney disease. To further our mission and goals and to provide accredited medical education for its membership and partners, the NephroNet leadership has organized this meeting and assembled a prestigious faculty to share some of the latest information to inform your practice now and in the future. The meeting will focus on new therapies in glomerular disease, hyperkalemia, polycystic kidney disease, and the science surrounding the biology of hypoxic inducible factors, podocyte biology, and other CKD disorders.

We would like to express our thanks to the pharmaceutical and biotech industry for their generous support, to our dedicated staff, colleagues, and friends for their untiring help, support and advice in planning and arranging this meeting.

We hope that you will enjoy the meeting and that your interaction with your colleagues from many different institutions will stimulate a creative exchange of ideas and will be personally rewarding. We also hope and trust that you will enjoy your visit to the very beautiful city of Atlanta.



James A. Tumlin MD

Founder and President, NephroNet

Program Description & Objectives

The NephroNet leadership is pleased to announce the first annual NephroNet Nephrology Update Meeting, which will be held at the Four Seasons Hotel July 27 - 29, 2018 in Mid-Town Atlanta, Georgia. This year's conference will focus on the latest updates in the treatment of chronic kidney disease and Glomerular Disease and feature many of the country's top lecturers.

Our objective is to facilitate collaboration between practicing physicians, clinical trial professionals and industry. We expect a broad range of physicians and nurses in attendance, and therefore have designed the session to be highly interactive, including extended Q/A sessions to maximize learnings. In addition, NephroNet will provide 12 accredited CME hours.

Registration fees include the following: attendance at all scientific sessions and keynotes, attendance at opening and closing ceremonies, attendance at welcome reception, access to select presentations, daily continental breakfast, lunch, and refreshments.

NephroNet Mission

NephroNet is an organization dedicated to providing resources to patients, practicing clinicians, and all individuals that are concerned with improving the care of patients with kidney disease. For patients, our goal is to be an educational resource that provides practical information to patients and their families. We endorse and are motivated as an organization to improve minority participation in CKD clinical research. We believe that by improving patient education of their disease, they will be better equipped to work with their physicians.



The NephroNet membership is composed of both academic and private physicians that work closely with the National Institutes of Health (NIH), American Society Nephrology, as well as large and small healthcare companies that are motivated to treat chronic kidney disease. The NephroNet membership has experts in all areas of kidney disease and is available for consultation that will ultimately bring new therapies to the renal community.

To learn more, visit www.nephronet.com or find us on facebook.

Additional Information

Contact: NephroNet, Inc.

Telephone: 404-790-0267

Website: www.nephronet.com

Email: jmoss@nephronet.com

AMA Credit Designation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Medical Association of Georgia through the joint providership of Southern Alliance for Physician Specialties CME and NephroNet, Incorporated. The Southern Alliance for Physician Specialties CME is accredited by the Medical Association of Georgia to provide continuing medical education for physicians.

The Southern Alliance for Physician Specialties CME designates this live activity for a maximum of 12.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Guest Faculty

Gerry Appel, M.D., Professor of Medicine at CUMC, Director, Glomerular Kidney Center

Kirk Campbell, M.D., Mount Sinai School of Medicine

Fernando Fervenza, M.D., Professor of Medicine, Mayo Clinic

Dick Glassock, M.D., Professor of Medicine, Emeritus Chairman, UCLA School of Medicine

Volker Haas, M.D., Krick-Brooks Professor of Medicine, Vanderbilt University Renal Division

Richard Lafayette, M.D., Professor of Medicine; Nephrology, Stanford University-San Francisco, California

Biff Palmer, M.D., Professor of Medicine Nephrology, UT Southwestern Renal Division

Samir Parikh, M.D., Associate Professor of Medicine, The Ohio State School of Medicine Renal Division

Frederic Rahbari, M.D., Associate Professor of Medicine, Emory University School of Medicine Renal Division

James A. Tumlin M.D., President NephroNet Clinical Trials Consortium

Program Agenda

Friday, July 27, 2018

6:00 p.m. NephroNet President Address
to Welcome Reception and Hors d'oeuvres, 50th Floor
9:00 p.m. **James A. Tumlin, M.D.**

Saturday, July 28, 2018

7:00 a.m. Breakfast Buffett

Program Agenda Continued

Saturday, July 28, 2018

- 8:00 a.m. IgA Nephropathy: Pathogenesis and Role of Lectin Complement Activation-Evolving Therapies
Richard Lafayette, M.D.
- 9:00 a.m. Hyperkalemia: Physiology and Treatment Mixing the New and the Old?
Biff Palmer, M.D.
- 10:00 a.m. Refreshment Break
- 10:30 a.m. Thrombotic Microangiopathies: Role of Complement Activation-Disease Manifestations and Novel Therapies
Gerry Appel, M.D.
- 11:30 a.m. Retained Products of Uremia: The “Forgotten Toxins” And their Contribution to ESRD Morbidity & Mortality
James A. Tumlin, M.D.
- 12:30 p.m. Working Lunch
Lupus Nephritis: Correlation Between Clinical Endpoint and Long-Term Outcomes. The need for Serial Renal Biopsies
Samir Parikh, M.D.
- 1:30 p.m. Podocyte Biology: Pathophysiology and Clinical Applications
Kirk Campbell, M.D.
- 2:30 p.m. Membranous Glomerulopathy: Great Strides-Biomarkers and the Use of Old and New Therapies
Fernando Fervenza, M.D.
- 3:30 p.m. Polycystic Kidney Disease: Clinical Management and the Role of Tolvaptan
Frederic Rahbari, M.D.
- 4:30 p.m. Fibrillary Glomerulopathy: “The Rare Disease that We Do Not Understand and Have No Treatment for”
Dick Glassock, M.D.
- 5:30 p.m. Savannah Room / Four Seasons Hotel
Dinner Reception
- 7:00 p.m. Update on the Biology of Hypoxic Inducible Factors: Understanding the Benefits and Limitations of HIF Agonists
Volker Haase, M.D.

Sunday, July 29, 2018

- 7:00 a.m. Continental Breakfast
- 8:00 a.m. ANCA Associated Vasculitis: Pathogenesis and Role of Complement Activation
Fernando Fervenza, M.D.
- 9:00 a.m. Calciphylaxis: Link Between Dialysis-Induced Vitamin K Deficiency and Soft Tissue Calcification
James Tumlin, M.D.



Cara Therapeutics is a clinical-stage biotechnology company located in Stamford, CT focused on developing and commercializing new chemical entities designed to fundamentally change the way pruritus is managed in CKD patients. We aim to achieve this by developing new products that selectively target the body's peripheral kappa opioid receptors. Cara is developing a novel and proprietary class of product candidates that target the body's peripheral nervous system and have demonstrated initial efficacy in patients with pruritus without inducing many of the undesirable side effects typically associated with currently available anti-pruritic therapies. Their lead candidate, KORSUVA™ is an IV formulation for use in hemodialysis patients suffering from moderate-to-severe pruritus.



Relypsa, Inc., a Vifor Pharma Group company, is a biopharmaceutical company focused on the discovery, development and commercialization of polymeric medicines for patients with conditions that are often overlooked and undertreated and can be addressed in the gastrointestinal tract. The Company's first medicine, Veltassa® (patiromer) for oral suspension, was developed based on Relypsa's rich legacy in polymer science. More information is available at www.relypsa.com.

Our Sponsors

GOLD LEVEL



EMD Serono is part of the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the United States and Canada. EMD Serono has proven expertise in neurology, fertility and endocrinology, as well as a strong pipeline in oncology, immuno-oncology and neurology/immunology.

GOLD LEVEL



OMEROS

Omeros is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases and disorders of the central nervous system.

BRONZE LEVEL



Akebia Therapeutics, Inc. is a biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on delivering innovative therapies to patients with kidney disease through hypoxia-inducible factor biology. For more information, please visit our website at www.akebia.com.

BRONZE LEVEL

Epizon

Epizon Pharma, Inc. was organized in 2015 to focus on the development of products for the treatment of renal and cardiovascular disease and the common complications shared by both diseases – calcification of the vasculature. The Company's initial drug addresses calciphylaxis, one of the most severe forms of calcification in renal patients, also known as calcific uremic arteriopathy (CUA).

Exhibitors and Supporting Companies

Mallinckrodt Pharmaceuticals

Mallinckrodt Pharmaceuticals is a multibillion dollar specialty pharmaceutical company focused on our mission: Managing Complexity. Improving Lives. We provide medicines to address unmet patient needs, stemming from 150 years of using our unique strengths, experience and expertise to help improve people's lives.

Relypsa, Inc

Keryx Biopharmaceuticals, Inc.

Retrophin, Inc.

Retrophin is a biopharmaceutical company dedicated to delivering life-changing therapies to people living with rare diseases who have few, if any, treatment options.

Genzyme Corporation

Pioneering research of lysosomal storage disorders

Lysosomal storage disorders (LSDs)—a group of rare genetic conditions caused by enzyme deficiencies—are a cornerstone of our business, and the medical area for which we are most well-known. These disorders are known as 'orphan diseases' and affect only a few thousand people worldwide.

Our first ten years of research focused primarily on finding a treatment for a LSD called Gaucher disease, the success of which established our leadership in the rare disease community. Over the next 2 decades we expanded our focus to include other LSDs including Fabry disease, Pompe disease and Mucopolysaccharidosis I (MPS I).

Our breakthrough work in genetic engineering and recombinant DNA manufacturing has enabled the large-scale production of enzyme replacement therapies (ERTs). ERTs work by breaking down the fatty substance that accumulates in peripheral cells due to the lack of native enzyme.

Otsuka America Pharmaceutical, Inc.

Otsuka in the U.S. has several pharmaceutical companies in the U.S. and we are all proud to be a part of the Otsuka Group. We share the global vision of a commitment to creativity and innovation and the consequent development and promotion of new products and innovative solutions for better health worldwide.